Department of Atherosclerosis, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.
Department of Cardiovascular, the Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China.
Sci Rep. 2016 Nov 10;6:36823. doi: 10.1038/srep36823.
Familial hypercholesterolemia (FH) is an autosomal dominant disorder. Although genetic testing is an important tool for detecting FH-causing mutations in patients, diagnostic methods for young patients with severe hypercholesterolemia are understudied. This study compares the target exome sequencing (TES) technique with the DNA resequencing array technique on young patients with severe hypercholesterolemia. A total of 20 unrelated patients (mean age 14.8 years) with total cholesterol > 10 mmol/L were included. 12 patient samples were processed by DNA resequencing array, 14 patient samples were processed by TES, and 6 patient samples were processed by both methods. Functional characterization of novel mutations was performed by flow cytometry. The mutation detection rate (MDR) of DNA resequencing array was 75%, while the MDR of TES was 100%. A total of 27 different mutations in the LDLR were identified, including 3 novel mutations and 8 mutations with previously unknown pathogenicity. Functional characterization of c.673delA, c.1363delC, p.Leu575Phe and p.Leu582Phe variants found that all of them are pathogenic. Additionally, 7 patients were diagnosed with Heterozygous FH (HeFH) in which lipid levels were significantly higher than common HeFH patients. This data indicates that TES is a very efficient tool for genetic diagnosis in young patients with severe hypercholesterolemia.
家族性高胆固醇血症(FH)是一种常染色体显性遗传疾病。尽管基因检测是检测 FH 致病突变的重要工具,但对于严重高胆固醇血症的年轻患者的诊断方法研究较少。本研究比较了目标外显子组测序(TES)技术与 DNA 重测序阵列技术在严重高胆固醇血症年轻患者中的应用。共纳入 20 名无亲缘关系的严重高胆固醇血症患者(平均年龄 14.8 岁,总胆固醇>10mmol/L)。12 份患者样本采用 DNA 重测序阵列进行处理,14 份患者样本采用 TES 进行处理,6 份患者样本同时采用两种方法进行处理。通过流式细胞术对新突变进行功能特征分析。DNA 重测序阵列的突变检测率(MDR)为 75%,而 TES 的 MDR 为 100%。共鉴定出 LDLR 中的 27 种不同突变,包括 3 种新突变和 8 种以前未知致病性的突变。对 c.673delA、c.1363delC、p.Leu575Phe 和 p.Leu582Phe 变异体的功能特征分析表明,它们均具有致病性。此外,7 名患者被诊断为杂合子家族性高胆固醇血症(HeFH),其血脂水平明显高于常见 HeFH 患者。这些数据表明 TES 是一种非常有效的遗传诊断工具,适用于严重高胆固醇血症的年轻患者。